Table of Contents
ISRN Hematology
Volume 2013 (2013), Article ID 847672, 7 pages
http://dx.doi.org/10.1155/2013/847672
Research Article

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation

1Unit of Hematology, Clinical Pathology Service, Hospital de Clínicas de Porto Alegre, 90035-903 Porto Alegre, RS, Brazil
2Laboratory of Cell Culture and Molecular Analysis of Hematopoietic Cells, Hospital de Clínicas de Porto Alegre, 90035-903 Porto Alegre, RS, Brazil
3Hematology and Bone Marrow Transplantation, Hospital de Clínicas de Porto Alegre, 90035-903 Porto Alegre, RS, Brazil

Received 29 April 2013; Accepted 29 May 2013

Academic Editors: A. Bosly and A. Gatt

Copyright © 2013 Suzane Dal Bó et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Bataille and J. L. Harousseau, “Multiple myeloma,” The New England Journal of Medicine, vol. 336, no. 23, pp. 1657–1665, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Barlogie, J. Schaughnessy, N. Munshi, and J. Epstein, “Plasma cell myeloma,” in Williams Hematology, E. Beutler, M. A. Lichtman, B. S. Coller, and T. I. Kipps, Eds., pp. 1279–1298, Mac Graw Hill, New York, NY, USA, 6 edition, 2001. View at Google Scholar
  3. S. V. Rajkumar, M. A. Gertz, R. A. Kyle, and P. R. Greipp, “Current therapy for multiple myeloma,” Mayo Clinic Proceedings, vol. 77, no. 8, pp. 813–822, 2002. View at Google Scholar · View at Scopus
  4. G. R. Mundy, “Investigation, prophilaxis, and treatment of bone Disease. Internacional Myeloma Gand Round,” The Lancet Oncology, vol. 2, pp. 573–574, 2001. View at Google Scholar
  5. B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Google Scholar · View at Scopus
  6. R. A. Kyle, J. A. Child, K. Anderson et al., “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group,” British Journal of Haematology, vol. 121, no. 5, pp. 749–757, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. R. Greipp, J. San Miguel, B. G. M. Durie et al., “International staging system for multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3412–3420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. F. San Miguel, N. C. Gutiérrez, G. Mateo, and A. Orfao, “Conventional diagnostics in multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1510–1519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Lioznov, A. Badbaran, B. Fehse, U. Bacher, A. R. Zander, and N. M. Kröger, “Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques,” Bone Marrow Transplantation, vol. 41, no. 10, pp. 913–916, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Rawstron, F. E. Davies, R. Dasgupta et al., “Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation,” Blood, vol. 100, no. 9, pp. 3095–3100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Zhao, Q. Huang, M. Slovak, and L. Weiss, “Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow,” American Journal of Clinical Pathology, vol. 125, no. 6, pp. 895–904, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Almeida, A. Orfao, G. Mateo et al., “Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance,” Pathologie Biologie, vol. 47, no. 2, pp. 119–127, 1999. View at Google Scholar · View at Scopus
  13. J. E. San Miguel, R. Garcia-Sanz, M. Gonzalez, and A. Orfao, “Immunophenotype and DNA cell content in multiple myeloma,” Bailliere's Clinical Haematology, vol. 8, no. 4, pp. 735–759, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Almeida, A. Oreao, M. Ocqueteau et al., “High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma,” British Journal of Haematology, vol. 107, no. 1, pp. 121–131, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Harada, M. M. Kawano, N. Huang et al., “Phenotypic difference of normal plasma cells from mature myeloma cells,” Blood, vol. 81, no. 10, pp. 2658–2663, 1993. View at Google Scholar · View at Scopus
  16. A. C. Rawstron, A. Orfao, M. Beksac et al., “Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders,” Haematologica, vol. 93, no. 3, pp. 431–438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. S. San Miguel, J. Almeida, G. Mateo et al., “Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome,” Blood, vol. 99, no. 5, pp. 1853–1856, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. E. Sarasquete, R. García-Sanz, D. González et al., “Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry,” Haematologica, vol. 90, no. 10, pp. 1365–1372, 2005. View at Google Scholar · View at Scopus
  19. G. M. Manzanera, J. F. S. M. Izquierdo, and A. O. de Matos, “Immunophenotyping of plasma cells in multiple myeloma,” Methods in molecular medicine, vol. 113, pp. 5–24, 2005. View at Google Scholar · View at Scopus
  20. A. C. Rawstron, R. G. Owen, F. E. Davies et al., “Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage,” British Journal of Haematology, vol. 97, no. 1, pp. 46–55, 1997. View at Google Scholar · View at Scopus
  21. A. Rawstron, S. Barrans, D. Blythe et al., “Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression,” British Journal of Haematology, vol. 104, no. 1, pp. 138–143, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Van Camp, B. G. M. Durie, C. Spier et al., “Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19),” Blood, vol. 76, no. 2, pp. 377–382, 1990. View at Google Scholar · View at Scopus
  23. P. Lin, R. Owens, G. Tricot, and C. S. Wilson, “Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma,” American Journal of Clinical Pathology, vol. 121, no. 4, pp. 482–488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Liu, C. Yuan, J. Heinerich et al., “Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study,” Leukemia and Lymphoma, vol. 49, no. 2, pp. 306–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. G. Owen, A. C. Rawstron, F. W. Cremer et al., “Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice,” British Journal of Haematology, vol. 128, no. 5, pp. 732–734, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Corradini, M. Cavo, H. Lokhorst et al., “Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma,” Blood, vol. 102, no. 5, pp. 1927–1929, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. F. Christine, J. Harrison, A. Victor Hoffbrand, and M. N. Potter, “Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis,” British Journal of Haematology, vol. 105, no. 1, pp. 7–24, 1999. View at Google Scholar · View at Scopus
  28. B. P. Simões, “Avaliação de doença residual mínima pós transplante de medula óssea,” Medicina Medicina, vol. 33, pp. 433–442, 2000. View at Google Scholar
  29. I. Iacobucci, G. Saglio, G. Rosti et al., “Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients,” Clinical Cancer Research, vol. 12, no. 10, pp. 3037–3042, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Coustan-Smith, R. C. Ribeiro, P. Stow et al., “A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome,” Blood, vol. 108, no. 1, pp. 97–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Barlogie, R. A. Kyle, K. C. Anderson et al., “Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 929–936, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. R. P. Falcão and L. F. F. Dalmazzo, “O valor da Imunofenotipagem para o diagnóstico do mieloma múltiplo e na avaliação da doença residual mínima,” RevBrasde Hematol e Hemoter, vol. 29, no. 1, pp. 3–9, 2007. View at Google Scholar
  33. F. E. Davies, P. D. Forsyth, A. C. Rawstron et al., “The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma,” British Journal of Haematology, vol. 112, no. 3, pp. 814–819, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. C. S. Zent, C. S. Wilson, G. Tricot et al., “Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation,” Blood, vol. 91, no. 9, pp. 3518–3523, 1998. View at Google Scholar · View at Scopus
  35. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. F. E. Davies, A. C. Rawstron, R. G. Owen, and G. J. Morgan, “Minimal residual disease monitoring in multiple myeloma,” Best Practice and Research, vol. 15, no. 1, pp. 197–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. R. G. Owen, R. J. Johnson, A. C. Rawstron et al., “Assessment of IgH PCR strategies in multiple myeloma,” Journal of Clinical Pathology, vol. 49, no. 8, pp. 672–675, 1996. View at Google Scholar · View at Scopus
  38. E. Pérez-Persona, M.-B. Vidriales, G. Mateo et al., “New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells,” Blood, vol. 110, no. 7, pp. 2586–2592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Paiva, M.-B. Vidriales, J. Cerveró et al., “Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation,” Blood, vol. 112, no. 10, pp. 4017–4023, 2008. View at Publisher · View at Google Scholar · View at Scopus